DEFA14A: Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion

Akero Therapeutics has agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash, including a contingent value right tied to regulatory approval of efruxifermin.

Summary

• Akero Therapeutics, Inc. (Akero) has entered into an Agreement and Plan of Merger with Novo Nordisk A/S (Parent) and NN Invest Sub, Inc. (Merger Sub).
• Each share of Akero common stock will be converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR).
• Each CVR represents the right to receive $6.00 in cash if FDA Approval for efruxifermin (EFX) for subcutaneous injection for the treatment of patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis is received by June 30, 2031.
• The upfront cash portion represents an equity value of approximately $4.7 billion.
• The combined upfront and potential contingent value payment represents, if achieved, an equity value of approximately $5.2 billion.
• The transaction has been unanimously approved by Akero's Board of Directors and is expected to close around year-end.
• Consummation of the merger is subject to customary closing conditions, including Akero shareholder approval, expiration or termination of HSR Act waiting periods, and obtainment of antitrust/foreign direct investment clearances.
• Akero will be required to pay Parent a termination fee of $165,000,000 under specified circumstances, such as accepting a Superior Offer.
• Parent will be required to pay Akero a reverse termination fee of $185,000,000 if the merger is not consummated due to certain antitrust or foreign direct investment law conditions not being satisfied.
• Outstanding In-the-Money Options and Company RSUs will be cancelled and converted into a cash payment plus one CVR per share; Out-of-the-Money Options will be cancelled for no consideration if unexercised at the Effective Time.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to shareholders and provides Akero's lead asset with the resources of a major pharmaceutical company, significantly de-risking its development and commercialization path, despite the contingent nature of part of the consideration.

Positives

• Shareholders will receive a significant upfront cash payment of $54.00 per share.
• The upfront cash consideration represents a 19% premium to Akero's 30-day Volume Weighted Average Price (VWAP) and a 42% premium to its closing price on May 19, 2025, prior to market speculation.
• The potential for an additional $6.00 per share via a Contingent Value Right (CVR) offers further upside, bringing the total potential premium to 32% to 30-day VWAP and 57% to the May 19, 2025 closing price, if the FDA approval milestone is met.
• Akero's innovative efruxifermin (EFX) program will complement Novo Nordisk's leadership in GLP-1 based metabolic treatments, potentially accelerating its development and commercialization.
• The transaction has been unanimously approved by Akero's Board of Directors, indicating strong internal support for the terms.

Negatives

• The $6.00 per share CVR payment is contingent on FDA approval of EFX for compensated cirrhosis due to MASH by June 30, 2031, with no assurance that this milestone will be achieved.
• CVRs are contractual rights only and are non-transferable, limiting liquidity for holders.
• Out-of-the-Money Options that remain unexercised at the Effective Time will be cancelled for no consideration.
• Akero is subject to a $165,000,000 termination fee if it accepts a superior offer or changes its recommendation under certain conditions.
• Parent's diligence obligation for EFX is limited to 'Commercially Reasonable Efforts' and ceases upon the earlier of the first FDA filing or failure of a primary endpoint in the SYNCHRONY Histology or Outcomes trials, which could impact the likelihood of the CVR milestone.

Risks

• There is no assurance that the CVR Milestone (FDA Approval for efruxifermin) will be achieved by June 30, 2031, or that the Milestone Payment will become payable to holders of CVRs.
• Uncertainties exist regarding the ability to obtain Akero shareholder approval for the merger.
• The transaction is subject to securing regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) and foreign direct investment laws, which may not be obtained on expected terms, at all, or in a timely manner.
• The possibility that competing offers for Akero will be made.
• The effects of the transaction (or its announcement/pendency) on relationships with associates, customers, manufacturers, suppliers, employees, other business partners, or governmental entities.
• Difficulty in predicting the timing or outcome of FDA approvals or actions, if any, for EFX.
• The impact of competitive products and pricing in the metabolic disease market.
• Parent may not realize the potential benefits of the transaction.
• Transaction costs and actual or contingent liabilities.
• The transaction may divert management's attention from Akero's ongoing business operations or otherwise disrupt them.
• Certain restrictions during the pendency of the transaction may impact Akero's ability to pursue business opportunities or strategic transactions.
• Risks associated with litigation relating to the transaction.
• The ability to maintain or expand regulatory approvals or commercialize Akero's products.
• The results of any ongoing or future clinical trials for EFX may not satisfy U.S. or non-U.S. regulatory authorities.
• Uncertainty associated with current worldwide economic and financial conditions, including inflation, interest rates, natural disasters, and military conflicts.

Future Outlook

Akero's innovative efruxifermin (EFX) program is expected to complement Novo Nordisk's leadership in GLP-1 based metabolic treatments. Novo Nordisk's world-leading capabilities in cardio-metabolic disease are anticipated to enhance and accelerate the evaluation of EFX in the Phase 3 SYNCHRONY program, prepare for a successful commercial launch, and facilitate the delivery of EFX to patients globally. However, the contingent value right (CVR) payment is dependent on FDA approval of EFX for compensated cirrhosis due to MASH by June 30, 2031, and there is no assurance that this milestone will be achieved.

Management Comments

• "We are excited to enter into this transaction with Novo Nordisk, which follows a comprehensive review undertaken by our Board of Directors, delivers meaningful value to Akero shareholders, and positions us to expand treatment options for people around the globe through Novo Nordisk’s industry-leading development capabilities and commercial infrastructure." Andrew Cheng, M.D., Ph.D, President and CEO of Akero Therapeutics.

Industry Context

This acquisition significantly strengthens Novo Nordisk's presence in the metabolic disease treatment landscape, particularly in metabolic dysfunction-associated steatohepatitis (MASH). By integrating Akero's efruxifermin (EFX) program, an FGF21 analog, Novo Nordisk diversifies its portfolio beyond its successful GLP-1 based treatments. This strategic move positions Novo Nordisk to address a high unmet medical need in MASH, a disease with a complex pathology and a growing patient population. The acquisition provides EFX with the substantial resources, development expertise, and global commercial infrastructure of a major pharmaceutical company, potentially accelerating its path to market and enhancing its competitive standing against other therapies in development for MASH.

Comparison to Industry Standards

• The acquisition premium offered to Akero shareholders (19% to 30-day VWAP and 42% to pre-speculation price) is generally considered attractive within the biotechnology and pharmaceutical M&A sector, especially for a clinical-stage company.
• The inclusion of a Contingent Value Right (CVR) is a common and accepted mechanism in biotech acquisitions, particularly for late-stage clinical assets like EFX, to bridge valuation gaps between buyer and seller and to share the risks and rewards of future regulatory and commercial success.
• Novo Nordisk's established leadership in cardio-metabolic diseases, with blockbuster drugs like Ozempic and Wegovy, provides a robust platform for the development and potential commercialization of EFX, offering a significant advantage compared to Akero's capabilities as a standalone clinical-stage entity.
• Akero's ongoing Phase 3 SYNCHRONY program for EFX, encompassing Histology, Outcomes, and Real-World trials, represents a comprehensive and rigorous clinical development strategy, aligning with industry best practices for de-risking and maximizing the market potential of a novel therapy for MASH.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes risks associated with litigation relating to the transaction.
• Akero will give Parent the opportunity to participate in the defense, settlement, or mooting disclosures relating to any litigation or threatened litigation against Akero and/or its directors or officers relating to the Transactions, and no settlement shall be agreed to without Parent's prior written consent.

Related Party Transactions

• The filing mentions that any Contract with any Affiliate (other than another Acquired Corporation), director or executive officer, or Person holding five percent (5%) or more of the Shares, is considered a Material Contract, but no specific new related party dealings in the context of the merger are detailed.

Stakeholder Impact

• **Shareholders**: Will receive a significant cash premium for their shares and potential additional value through a non-transferable Contingent Value Right (CVR) tied to the regulatory success of efruxifermin (EFX).
• **Employees**: Continuing employees will receive base salary/hourly wage rates and target annual/short-term cash incentive opportunities at least equal to pre-closing levels for one year. They will also receive substantially similar broad-based employee benefits and severance benefits no less favorable than similarly situated employees of Parent. Service credit will be given for eligibility and vesting in Parent's benefit plans.
• **Customers/Patients**: The acquisition by Novo Nordisk is expected to enhance and accelerate the development and potential commercialization of EFX, potentially bringing a new treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH) to market more efficiently.
• **Directors and Officers**: Current and former directors and officers will retain indemnification rights, advancement of expenses, and exculpation from liabilities for acts or omissions occurring prior to the Effective Time for a period of six years. Directors and officers insurance coverage will also be maintained for six years post-merger.

Next Steps

• Akero to prepare and file a preliminary proxy statement with the SEC within 10 business days of October 9, 2025.
• Akero to establish a record date, duly call, convene, and hold a meeting of its stockholders to vote upon the adoption of the Merger Agreement.
• Parent, a direct or indirect wholly owned subsidiary of Parent, and a rights agent will enter into a Contingent Value Rights Agreement at or prior to the Effective Time.
• The merger is expected to close around year-end, subject to the satisfaction of customary closing conditions, including shareholder approval and regulatory clearances.
• Parent and Akero will use reasonable best efforts to obtain any required clearances under the HSR Act and other applicable Antitrust Laws.
• Parent will use Commercially Reasonable Efforts to conduct the SYNCHRONY Histology and SYNCHRONY Outcomes clinical trials until the Termination Date (June 30, 2031) or earlier cessation conditions.
• Upon achievement of the primary endpoint in both SYNCHRONY Histology and SYNCHRONY Outcomes clinical trials, Parent will file for and seek FDA Approval for EFX for compensated cirrhosis due to MASH.
• Akero will cooperate with Parent to delist the Shares from Nasdaq and deregister them under the Exchange Act as promptly as practicable after the Effective Time.

Key Dates

Recommendation

The acquisition by Novo Nordisk offers Akero shareholders a substantial and immediate cash premium of $54.00 per share, representing a 42% premium to the stock's price prior to market speculation. Additionally, the contingent value right (CVR) of $6.00 per share provides further upside potential if efruxifermin (EFX) achieves FDA approval for compensated cirrhosis due to MASH by June 30, 2031. This structure provides both immediate value and participation in the future success of Akero's lead asset, while transferring the significant development and commercialization risks to a well-capitalized industry leader. The unanimous board approval and the strategic fit with Novo Nordisk's metabolic disease portfolio further support the attractiveness of this deal for Akero shareholders.

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, Efruxifermin, EFX, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Compensated Cirrhosis, FDA Approval, Contingent Value Right, CVR, Biologics License Application, BLA, SYNCHRONY, Clinical Trials, Pharmaceutical, Biotechnology, Healthcare, Drug Development